Literature DB >> 7615829

A functional cyclic AMP response element plays a crucial role in neuroendocrine cell type-specific expression of the secretory granule protein chromogranin A.

H Wu1, S K Mahata, M Mahata, N J Webster, R J Parmer, D T O'Connor.   

Abstract

Chromogranin A, a soluble acidic protein, is a ubiquitous component of secretory vesicles throughout the neuroendocrine system. We reported previously the cloning and initial characterization of the mouse chromogranin A gene promoter, which showed that the promoter contains both positive and negative domains and that a proximal promoter spanning nucleotides -147 to +42 bp relative to the transcriptional start site is sufficient for neuroendocrine cell type-specific expression. The current study was undertaken to identify the particular elements within this proximal promoter that control tissue-specific expression. We found that deletion or point mutations in the potential cAMP response element (CRE) site at -68 bp virtually abolished promoter activity specifically in neuroendocrine (PC12 chromaffin or AtT20 corticotrope) cells, with little effect on activity in control (NIH3T3 fibroblast) cells; thus, the CRE box is necessary for neuroendocrine cell type-specific activity of the chromogranin A promoter. Furthermore, the effect of the CRE site is enhanced in the context of intact (wild-type) promoter sequences between -147 and -100 bp. DNase I footprint analysis showed that these regions (including the CRE box) bind nuclear proteins present in both neuroendocrine (AtT20) and control (NIH3T3) cells. In AtT20 cells, electrophoretic mobility shift assays and factor-specific antibody supershifts showed that an oligonucleotide containing the chromogranin A CRE site formed a single, homogeneous protein-DNA complex containing the CRE-binding protein CREB. However, in control NIH3T3 cells we found evidence for an additional immunologically unrelated protein in this complex. A single copy of this oligonucleotide was able to confer neuroendocrine-specific expression to a heterologous (thymidine kinase) promoter, albeit with less fold selectivity than the full proximal chromogranin A promoter. Hence, the CRE site was partially sufficient to explain the neuroendocrine cell type specificity of the promoter. The functional activity of the CRE site was confirmed through studies of the endogenous chromogranin A gene. Northern mRNA analysis showed that expression of the endogenous chromogranin A gene was stimulated seven- to eightfold by cAMP in PC12 cells, whereas no induction occurred in the NIH3T3 cells. Similar cAMP induction was obtained with the transfected chromogranin A promoter in PC12 cells, and abolition of the CRE site (by deletion or point mutation) eliminated the induction. Thus, the CRE site in the chromogranin A proximal promoter is functional and plays a crucial, indeed indispensable, role in neuroendocrine-specific expression of the gene. These results also provide insight into transcriptional mechanisms governing acquisition of the neuroendocrine secretory phenotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7615829      PMCID: PMC185231          DOI: 10.1172/JCI118069

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  Characterization of a bipartite activator domain in transcription factor CREB.

Authors:  K K Yamamoto; G A Gonzalez; P Menzel; J Rivier; M R Montminy
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

2.  K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases.

Authors:  H Kase; K Iwahashi; S Nakanishi; Y Matsuda; K Yamada; M Takahashi; C Murakata; A Sato; M Kaneko
Journal:  Biochem Biophys Res Commun       Date:  1987-01-30       Impact factor: 3.575

Review 3.  Transcription factors. 1: bZIP proteins.

Authors:  H C Hurst
Journal:  Protein Profile       Date:  1994

4.  Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements.

Authors:  W Lee; P Mitchell; R Tjian
Journal:  Cell       Date:  1987-06-19       Impact factor: 41.582

5.  Immunological studies on the occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors.

Authors:  R Weiler; R Fischer-Colbrie; K W Schmid; H Feichtinger; G Bussolati; L Grimelius; K Krisch; H Kerl; D O'Connor; H Winkler
Journal:  Am J Surg Pathol       Date:  1988-11       Impact factor: 6.394

6.  Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands.

Authors:  D T O'Connor; D Burton; L J Deftos
Journal:  Life Sci       Date:  1983-10-24       Impact factor: 5.037

7.  Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum.

Authors:  D T O'Connor
Journal:  Regul Pept       Date:  1983-07

8.  Firefly luciferase gene: structure and expression in mammalian cells.

Authors:  J R de Wet; K V Wood; M DeLuca; D R Helinski; S Subramani
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

9.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.

Authors:  L A Greene; A S Tischler
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

10.  Identification of a cyclic-AMP-responsive element within the rat somatostatin gene.

Authors:  M R Montminy; K A Sevarino; J A Wagner; G Mandel; R H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

View more
  7 in total

1.  Stimulus coupling to transcription versus secretion in pheochromocytoma cells. Convergent and divergent signal transduction pathways and the crucial roles for route of cytosolic calcium entry and protein kinase C.

Authors:  K Tang; H Wu; S K Mahata; M Mahata; B M Gill; R J Parmer; D T O'Connor
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Chromogranin A transcription and gene expression in Folliculostellate (TtT/GF) cells inhibit cell growth.

Authors:  Gail A Stilling; Jill M Bayliss; Long Jin; Heyu Zhang; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

3.  Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).

Authors:  L Taupenot; S K Mahata; H Wu; D T O'Connor
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

4.  A haplotype variant of the human chromogranin A gene (CHGA) promoter increases CHGA expression and the risk for cardiometabolic disorders.

Authors:  Lakshmi Subramanian; Abrar A Khan; Prasanna K R Allu; Malapaka Kiranmayi; Bhavani S Sahu; Saurabh Sharma; Madhu Khullar; Ajit S Mullasari; Nitish R Mahapatra
Journal:  J Biol Chem       Date:  2017-06-30       Impact factor: 5.157

5.  Genetic variation within a metabolic motif in the chromogranin a promoter: pleiotropic influence on cardiometabolic risk traits in twins.

Authors:  Fangwen Rao; Stephane Chiron; Zhiyun Wei; Maple M Fung; Yuqing Chen; Gen Wen; Srikrishna Khandrika; Michael G Ziegler; Beben Benyamin; Grant Montgomery; John B Whitfield; Nicholas G Martin; Jill Waalen; Bruce A Hamilton; Sushil K Mahata; Daniel T O'Connor
Journal:  Am J Hypertens       Date:  2011-09-15       Impact factor: 2.689

6.  Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression.

Authors:  L Jin; B W Scheithauer; W F Young; D H Davis; G G Klee; R V Lloyd
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

7.  Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure.

Authors:  Y Chen; F Rao; J L Rodriguez-Flores; N R Mahapatra; M Mahata; G Wen; R M Salem; P-A B Shih; M Das; N J Schork; M G Ziegler; B A Hamilton; S K Mahata; D T O'Connor
Journal:  Kidney Int       Date:  2008-04-23       Impact factor: 10.612

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.